What are the indications for Kerendia (finerenone) in adult patients with chronic kidney disease and type 2 diabetes, an estimated glomerular filtration rate (eGFR) of 25–90 mL/min/1.73 m², albuminuria, and serum potassium ≤5.0 mEq/L?

Indications for Kerendia (Finerenone)

Kerendia is indicated for two distinct patient populations: (1) adults with chronic kidney disease associated with type 2 diabetes who have albuminuria and eGFR >25 mL/min/1.73 m², and (2) adults with heart failure with LVEF ≥40%. 1

Primary Indication: CKD Associated with Type 2 Diabetes

Kerendia reduces the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in this population 1.

Specific Patient Criteria for CKD/T2D Indication:

According to the 2024 KDIGO guidelines, nonsteroidal MRAs like finerenone should be used in adults with type 2 diabetes, eGFR >25 mL/min/1.73 m², normal serum potassium concentration, and albuminuria (>30 mg/g [>3 mg/mmol]) despite maximum tolerated dose of RAS inhibitor 2.

Key eligibility parameters:

• eGFR threshold: >25 mL/min/1.73 m² (do not initiate below this level)
• Albuminuria requirement: >30 mg/g (>3 mg/mmol) - this is essential as finerenone is most appropriate for patients at high risk of CKD progression demonstrated by persistent albuminuria despite standard-of-care therapies 2
• Potassium requirement: Normal serum potassium concentration at baseline (ideally ≤4.8 mmol/L for initiation) 2
• Background therapy: Should already be on maximum tolerated RAS inhibitor (ACEi or ARB) 2

Treatment Positioning in CKD/T2D:

Finerenone may be added to a RAS inhibitor AND an SGLT2 inhibitor for treatment of type 2 diabetes and CKD 2. This represents a triple therapy approach for patients with residual risk despite first-line agents. The 2024 KDIGO guidelines explicitly state that nonsteroidal MRAs are most appropriate for adults with type 2 diabetes who are at high risk of CKD progression and cardiovascular events, as demonstrated by persistent albuminuria despite other standard-of-care therapies 2.

The 2022 KDIGO Diabetes guideline framework positions finerenone as an "additional drug with heart and kidney protection" layered on top of foundational therapies (metformin, SGLT2i, RAS blockade, statin) 3.

Secondary Indication: Heart Failure with LVEF ≥40%

Kerendia reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with preserved or mildly reduced ejection fraction (LVEF ≥40%) 1.

Critical Safety Considerations for Patient Selection:

Absolute Contraindications:

• Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, clarithromycin) 1
• Adrenal insufficiency 1
• Hypersensitivity to any component 1

Potassium-Based Initiation Algorithm:

The 2024 KDIGO guidelines provide explicit potassium thresholds 2:

For K+ ≤4.8 mmol/L:

• Initiate finerenone 10 mg daily if eGFR 25-59 mL/min/1.73 m²
• Initiate finerenone 20 mg daily if eGFR ≥60 mL/min/1.73 m²

For K+ 4.9-5.5 mmol/L:

• Continue current dose if already on finerenone
• Monitor K+ every 4 months

For K+ >5.5 mmol/L:

• Hold finerenone
• Do NOT initiate
• Consider dietary adjustments or medication changes to mitigate hyperkalemia
• Recheck K+ and consider reinitiation only when K+ ≤5.0 mmol/L

Monitoring Requirements:

Monitor serum potassium at 1 month after initiation, then every 4 months 2. This is critical as hyperkalemia is the most common adverse reaction, occurring in approximately 17% of patients in real-world data 4, though discontinuation rates remain low (1.5-2.3%) 1, 5.

Clinical Evidence Supporting Indications:

The FIDELIO-DKD trial demonstrated that finerenone reduced the risk of the primary composite kidney outcome (kidney failure, sustained ≥40% eGFR decline, or death from renal causes) by 18% (HR 0.82,95% CI 0.73-0.93, P=0.001) and cardiovascular outcomes by 14% (HR 0.86,95% CI 0.75-0.99, P=0.03) in patients with CKD and type 2 diabetes 5. The FIDELITY pooled analysis confirmed these benefits across diverse populations 6.

Important caveat: Recent data from the FIND-CKD trial showed finerenone also benefits patients with CKD WITHOUT diabetes (eGFR 25-90 mL/min/1.73 m², albuminuria 200-3500 mg/g), slowing eGFR decline by 0.7 mL/min/1.73 m²/year compared to placebo 7. However, this is not yet an FDA-approved indication as of the current label 1.

Common Pitfalls to Avoid:

1. Do not use finerenone as monotherapy - it should be added to, not replace, RAS inhibitors in the CKD/T2D population 2
2. Do not initiate if eGFR ≤25 mL/min/1.73 m² - this is below the evidence-based threshold 2
3. Do not overlook drug interactions - avoid grapefruit juice and carefully manage moderate CYP3A4 inhibitors with potassium monitoring 1
4. Do not initiate without checking baseline potassium - patients with elevated potassium at baseline have significantly higher hyperkalemia risk 2